ArticleAmerican journal of cancer research2025
Direct triangular comparison of tissue and serum growth differentiation factor 15 with host factors in colorectal cancer.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Osteocyte-Derived GDF15 Promotes Paclitaxel Resistance, Tumor Growth, and Bone Microenvironment Regulation in Prostate Cancer.Current issues in molecular biology · 2026Article
- Research progress on the biological function and molecular mechanism of GDF-15 in solid malignant tumors.World journal of surgical oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growth differentiation factor 15 (GDF-15) is a potential biomarker for colorectal cancer (CRC) and is associated with sarcopenia and cachexia. However, its clinical significance in CRC remains unclear. We investigated the clinical significance of GDF-15 in CRC patients by a unique triangular comparison of tissue and preoperative serum GDF-15 levels with host factors. We evaluated 428 tissue and 214 serum samples from 214 CRC patients. We measured tissue and serum levels of GDF-15 and assessed their association with oncological outcomes and host factors. While cancer tissue GDF-15 levels showed no significant associations with clinicopathological factors or survival, preoperative serum GDF-15 levels were significantly correlated with indicators of disease progression, such as advanced T stage and advanced pathological stage. High preoperative serum GDF-15 level was associated with poor disease-free survival and overall survival and was an independent prognostic factor for disease-free survival and overall survival. Significant correlations were observed between preoperative serum GDF-15 levels and host factors, including body mass index, psoas muscle mass index, intramuscular adipose tissue content, and C-reactive protein. In conclusion, preoperative serum GDF-15 reflects host factors such as body composition and inflammation and is a useful marker for the oncological management of CRC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.